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ABSTRACT
Worldwide cancer incidence is increasing, with viral infections including human papillomavirus (HPV)
responsible for a significantly higher number of cancer deaths in low- and middle-income countries
(LMICs) when compared to high income countries. Globally, in 2015, there were 72 national HPV vacci-
nation programmes, and 39 demonstration or pilot programmes. Despite HPV’s impact on both sexes, for
examples in malignancies such as oropharyngeal cancer (whose incidence is increasing across the world)
few countries have a gender-neutral vaccination policy. Herd protection and cost-effectiveness are impor-
tant considerations in potential extension of vaccination to males and while there is some suggestion that
a targeted vaccination programmes for “high risk” groups, such as men-who-have-sex-with-men (MSM)
may be preferable, a universal vaccination approach is the best solution to protect both men and women
from HPV-related cancer and sexually transmitted disease. Higher incidence of certain HPV-related male
cancers, lack of effective treatment, high prevalence of HIV, attitudes to MSM and sexual orientation, all
support a universal vaccination strategy for LMICs. Thus, policy-makers and healthcare providers in LMICs
need to take timely decisions to “prevent the preventable” by providing vaccination for both girls and boys.
There is a global gender difference in cancer 
incidence and mortality, with the burden in men 
being much higher than in women, in 2012, there 
were 126 cancer deaths per 100 000 men, and 83 for 
every 100 000 females.1,2 Cancer incidence is increas-
ing, with more than 60% of new cases occurring in 
Africa, Asia, and Central/South America, and two 
thirds of all cancer deaths occurring in the develop-
ing world.3 This burden can be partly explained by 
limited primary and secondary preventative strate-
gies and poor availability of detection and treatment 
methods.4 Significant cancer health disparities are 
evident, both across and within countries, including 
race and/or ethnicity, and avoidable inequalities, 
such as socioeconomic status and sexual activity.5,6 
It is this last factor – sexual activity and its link to 
sexually transmitted disease and cancer – which will 
be the focus of this perspective piece. 
VIRUSES AND CANCER: THE ROLE OF 
HUMAN PAPILLOMAVIRUS 
Viral infections, including Human Papillomavirus 
(HPV), are responsible for approximately 15% of all 
cancers worldwide, with low middle-income countries 
(LMICs) reporting much higher prevalence (e.g., 33% 
in sub-Saharan Africa).5 These infections lead to one 
fifth of cancer deaths in LMICs.7 HPV is the most 
common of all infections leading to cancer and hence 
is a crucial determinant of a significant global cancer 
burden; thus it demands the effective implementation 
of preventative or curative interventions.8
Globally, HPV is one of the most common sexually 
transmitted infections; there are numerous types of HPV, 
and varying degrees of risk linked with continual infec-
tion from each type. Many infections are short-lived 
and clinically unimportant, but repeated infection with 
particular strains of HPV causes a considerable burden 
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of disease in both men and women. HPV prevalence in 
men has been reported to be consistently higher than 
in females, due to a poorer natural immune response 
to HPV in men compared to women.9
Of the estimated 12.7 million cancers globally, 610 
000 were attributed to HPV infection.10 In women, 
cervical cancer has been linked to HPV, with only 
a small fraction being HPV-negative.11 More than 
40,000 of these cases occurred in men.12 Furthermore, 
in the future, males are predicted to have a greatly 
increasing incidence of anal, penile and oropharyn-
geal cancers.8,13 In countries with limited screening, 
mortality from cervical cancer far exceeds that of 
HPV-related disease in men; however, in the devel-
oped world, HPV cancer in men is similar to that of 
cervical cancer.14,15 However, unlike cervical cancer, 
there is no recommended screening programme for 
male HPV-related cancers.12 
OROPHARYNGEAL CANCER
Oropharyngeal cancer (OPC) shows a regional 
variation/heterogeneity in prevalence; in comparison 
to the high-income areas of North America, Northwest 
Europe, Australia and Japan (41–51%), the rest of 
the world has a much lower prevalence (13–24%).16 
The incidence of OPC is rising.17 Researchers have 
reported that men are twice as likely to develop HPV-
OPC than women;18 in Canada in 2012 the incidence 
rate of HPV-OPC was more than 4.5 times higher 
in males than females.19 In the USA, it is predicted 
that the number of HPV-related OPCs diagnosed per 
year will soon surpass the annual number of cervical 
cancer cases.20 
PENILE CANCER
Although penile cancer is a rare disease, its inci-
dence is higher in less developed countries, where it 
can account for approximately 10% of male cancers 
in parts of Africa, South America, and Asia.21 Around 
25-33% of penile cancers have been linked to HPV.22 
ANAL CANCER
Anal cancer incidence has increased rapidly in recent 
years in both males and females.23 In Africa, anal cancers 
present at a younger age and more advanced stage.24 
Crucial for male health, men-who-have-sex-with-men 
(MSM), who are estimated to be 5% of men, are dis-
proportionately more likely to develop anal cancer 
(15:1 compared with heterosexual men).14 These rates 
of HPV in males are similar to cervical cancer rates 
before the introduction of screening.25 HPV infection 
in men may also increase the risk of acquiring HIV 
infection26 as it potentially increases the permeabil-
ity of the genital lining to HIV.27 Accordingly, anal 
cancer incidence rates are significantly higher in 
HIV-positive men than HIV-negative (70–100 versus 
35 per 100,000 person years).28 This is a particular 
concern for LMICs who bear most of the burden of 
the global HIV epidemic.29 
OTHER HPV-RELATED DISEASES
In addition to cancer, infection with low-risk HPV 
strains (i.e., 6/11) is implicated in the development 
of anogenital warts (AGW).30 AGW are a significant 
burden in both men and women. Incidence of AGW 
appears to be similar worldwide, although there is little 
reliable LMIC data available.10 Prevalence estimates 
suggest 160–289 per 100,000 with a peak in males 
between the ages of 25–29 years.31 HPV infection 
can also be transmitted to a foetus by a pregnant 
mother, which could lead to RRP.14 There is a low 
prevalence of RRP (1–4 per 100,000), but it carries 
a high economic burden.32
Preventing HPV Associated Cancer: Vaccination 
Works
There is an effective solution to address the burden 
of HPV. Three HPV vaccines are licensed for use: 
a bivalent vaccine which protects against the two 
high risk HPV types (HPV16/18), a quadrivalent 
vaccine protecting against HPV 16/18, genital warts 
and RRP (by eliminating the maternal reservoir for 
HPV) (twHPV6/11); and a nonavalent vaccine that 
protects against nine of the most common virus types 
(HPV6/11/16/18/31/33/45/52/58). As the vaccine 
was initially approved for cervical cancer prevention 
in females, there are fewer studies of the vaccines’ 
preventative effect in males.33 However, the HPV 
vaccine has shown a good safety profile and efficacy 
in younger (aged 9 to 15)34–36 and older males (aged 
16–26).9,37,38 Furthermore, immunogenicity of the 
nonavalent vaccine in males was shown to be similar to 
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that in same age females.14 Pinto et al., demonstrated 
that HPV antibodies in the oral cavity in males can be 
generated through vaccination, but it will take many 
years before the research will be able to ascertain 
the effectiveness of HPV vaccination on male cancer 
outcomes.39 
Vaccination in Men – Pros and Cons
Despite the impact of HPV on males, only 11 
countries have implemented a funded universal HPV 
vaccination programme for both sexes. Crucially, 
coverage rates of these universal programmes are far 
from optimal, and range from 39.7% (USA) to over 
80% (Canada).40,41
Many countries that offer female-only vaccination 
programmes defend this decision based on the rationale 
that males will be protected as a result of herd protec-
tion.42 Many countries may not view HPV vaccination 
as a male issue, which may be particularly pertinent 
for LMICs, due to the huge cervical cancer burden in 
these countries. The incremental benefit of extending 
the vaccine to males is widely believed to be highly 
dependent on coverage in females. However, a European 
study demonstrated that vaccination of 12-year-old boys 
and girls versus a high uptake “girls-only” vaccination 
would be associated with substantial additional clinical 
benefits in terms of reduced incidence of HPV-related 
genital warts and carcinomas.43 
Herd protection is feasible if females have high HPV 
vaccine uptake and males only have sexual contact 
with vaccinated females; however, sexual behaviour is 
not that simplistic. Sexual mixing must be considered. 
Unvaccinated males risk HPV infection due to sex 
with partners of the same sex, older partners, foreign 
partners (due to migration or growing international 
travel for leisure or business) and sex workers.44
The major argument against implementation of 
universal vaccination has been the cost of this pro-
gram, and a number of studies initially did not find 
universal vaccination cost effective.45 However, there 
is mounting evidence that universal vaccination is 
cost-effective, at least in western populations,46 par-
ticularly when the costs associated with OPC47 and 
genital warts treatment48 are considered, and the dose 
schedules are changed from 3 to 2 doses.49 It has been 
proposed that considerations on the cost of universal 
HPV vaccination should be expanded to encompass 
the broader economic consequences and benefits to 
society. When universal vaccination is approached 
from the perspective of a life-time cost-benefit analy-
sis, wider economic benefits are demonstrated such 
as increased productivity, increased earnings and 
enhanced tax revenue.50 
From an ethical perspective, to “not fund” a vac-
cine for any group of individuals at risk of developing 
a vaccine-preventable disease is questionable; thus, 
including boys in vaccination campaigns is important 
to ensure equity in protection from HPV-related dis-
eases.51 It is also unfair for females to be expected to 
bear the burden of HPV prevention through vaccina-
tion, particularly when HPV is a virus that is sexually 
transmitted, and affects both sexes so prolifically.15,52 
With the burden of HPV-related disease in men in 
developed countries comparable to women, and no 
screening programme available in males for anal 
cancer or OPC, it is questionable to have a public 
health policy that is reliant on men being protected 
solely by herd immunity.15 
Targeted Vaccination Towards “High Risk” Men
It has been suggested that the female-only vac-
cine programme be extended to “high-risk” men 
such as MSM who do not profit from female-only 
vaccination strategies or those men with HIV in an 
effort to balance protection versus cost.53 Requiring 
the disclosure of sexual orientation as a prerequisite 
for vaccination could be seen as ethically question-
able.15 It is impractical and unethical to ask adolescent 
boys if they are likely to have sex with another male 
when they are older, and if so, would they consider 
HPV vaccination.54 In the UK, the Joint Committee 
on Vaccination and Immunisation (JCVI) issued a 
recommendation that MSM up to age 45 years should 
be offered HPV vaccination via Genito-Urinary Medi-
cine (GUM) and HIV clinics. A pilot programme is 
currently being undertaken in England. Superficially, 
this may seem to be a cost-effective solution, but a 
targeted MSM HPV vaccination programme may be 
difficult to implement, and may have limited efficacy 
in preventing HPV-related disease, as the HPV vac-
cine is thought to be most effective when given at a 
younger age (9–15 years), before exposure to HPV 
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through sexual contact and when immunogenicity 
is at its highest.55 In addition, most MSM are likely 
to have delayed in their presentation to a HCP and 
to have had multiple sexual partners with increased 
risk of HPV acquisition before they attend a sexual 
health clinic.56,57 There is evidence that once they do 
attend a GUM clinic, the majority of MSM will re-
attend within 24 months, which could facilitate the 
delivery of the HPV vaccine programme.58 There are 
also MSM who do not identify as gay or homosexual 
and will not disclose their sexual activity to a HCP, 
meaning that they will never be offered the vaccina-
tion. The discriminatory impact of this policy would 
be amplified in countries where homosexuality is 
illegal, a considerable issue in LMICs. 
Vaccination in LMICs – Current Situation and 
the Potential for Universal Vaccination 
The greatest public health impact of HPV vaccination 
will be in countries where large portions of the popula-
tion have limited or no access to secondary prevention 
cancer screening.59 However, there is no consideration 
of universal vaccination in LMICs, in fact the WHO 
guidelines do not include HPV vaccination of boys.60 
HPV vaccine recommendation needs to be widened 
with consideration given to inclusion of adolescent 
males in vaccination programmes in LMICs. 
Globally, HPV vaccination (routine use for ado-
lescent girls) has only been introduced in 35% of 
countries.61 In August 2015 there were an estimated 
72 national HPV vaccination programmes, and 39 
smaller scale demonstration or pilot programmes.40 
The largest proportion of national programmes were 
in high-income countries in Europe, with LMICs hav-
ing the most pilot programmes. There are still a large 
number of LMICs with no vaccination programmes.62 
According to the Program for Appropriate Tech-
nology in Health (PATH), since 2007, more than 
1,625,000 girls in LMICs have participated in HPV 
vaccine programmes, with 800,000 completing a full 
vaccine schedule. Forty-one countries (84%) reported 
coverage of 70% or higher; no project or programme 
had coverage of less than <50% (in comparison to 
USA’s 39.7% uptake). This high uptake suggests that 
if these programmes were extended, effective coverage 
of boys may also be achieved. 
Understandably, cost is a considerable barrier to HPV 
vaccination programmes in LMICs. WHO determines 
a threshold for cost-effectiveness as the cost of the 
intervention per disability-adjusted life year averted 
as less than 3 times the per capita gross domestic 
product (GDP) of a country. However, concerns have 
been raised about the universal applicability of this 
strategy, and whether affordability is truly reflected 
in this figure.63 By their nature, cost-effectiveness 
studies are applicable to the country from which the 
data was sourced. Studies in LMICs have largely 
focused on female vaccination for cervical cancer 
prevention. These studies are heterogeneous and 
some lack clarity regarding country-specific costs, 
including implementation of vaccination programs, 
and vaccine cost. However, overall the data supports 
cost-effectiveness, and potentially cost savings with 
the establishment of female vaccination programs, 
particularly where inadequate screening for cervical 
cancer is available.64,65 
The majority of studies incorporating male vac-
cination have focused on the developed world where 
vaccination costs are considerably higher. However, 
a Mexican study highlighted that a universal program 
with catch-up vaccination for both sexes would be the 
most effective strategy for prevention of HPV-related 
disease, but this optimal strategy increased cost per 
quality-adjusted life year (QALY) from approximately 
$3000USD to $16000USD.66 
To assist with costs in LMICs, a financing mecha-
nism is available through GAVI, the Vaccine Alliance, 
or the Pan American Health Organization (PAHO) 
Revolving Fund for Latin America and Caribbean 
countries, both of which reduce the per-dose cost. 
GAVI subsidises introduction of HPV vaccination 
in LMICs, until countries can afford the vaccines. 
GAVI has negotiated a low price of approximately 
$4.50 per dose (compared to $100 for high income 
countries), with low-income countries paying only 
a small fraction of this as a co-payment.67 The cost 
reductions supported by the GAVI alliance, would 
reduce expense for introduction of a universal vac-
cination program within LMICs. However, the actual 
reductions in vaccination delivery cost remain unclear 
and prevent accurate assessment of cost-effectiveness. 
This has been analysed by a number of LMIC pilot 
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projects, demonstrating that the differing methods of 
delivering the program, dependent on school attendance 
and population density, result in varying estimates 
of cost.68 The complexities in incorporating finan-
cial factors when making a determination regarding 
optimal HPV vaccination strategies in LMICs have 
been acknowledged by WHO, with an expert group 
convening to address these issues.69
Linking Health Interventions
Adolescents in LMICs face considerable health 
risks and health systems in these countries have dif-
ficulty ensuring access to appropriate cancer control 
measures. According to the WHO (2014),60 there is 
an opportunity to link the delivery of the vaccine with 
other adolescent health interventions, including vi-
sion screening, information provision, and life skills 
development (e.g., physical activity; menstrual hygiene 
education, sexual health education; other vaccines) 
(WHO, 2014).60 However, the introduction of HPV 
vaccination should not be delayed if other relevant 
health interventions cannot be introduced concur-
rently.60 Additionally, HPV vaccination provides the 
opportunity to include health education that focuses on 
modifying behaviours that lead to HPV transmission, 
and an opportunity to inform and educate women on 
screening, diagnosis, and treatment of precancerous 
lesions and cancer.60 
Enhancement of HPV Vaccine Coverage 
As has been discussed, many countries report low 
HPV vaccine uptake in males. In order to maximise 
benefit from vaccination, it is important to understand 
the factors that influence and enhance vaccine coverage. 
A key question is whether or not men would accept 
vaccination if offered. Many countries’ information 
campaigns are targeted to females-only, with a clear 
focus on cervical cancer. This connotation that HPV 
is a women’s problem, and its subsequent impact on 
primary prevention efforts is referred to as the “femi-
nisation of HPV.”33 This ‘feminisation’ is important 
as it impacts on how the general public, HCPs and 
policy makers view HPV and HPV vaccination as 
a female-only issue.33 If existing programmes are 
to be extended to boys, better health education and 
public information campaigns must maximise public 
awareness that HPV should be of concern to both 
sexes. However, knowledge is not always predictive 
of vaccine acceptance and uptake, with high uptake 
seen in populations with low knowledge.70 A recent 
meta-analysis of 22 studies (8360 participants) reported 
a moderate level of acceptability among men (overall 
mean acceptability of 56.6%; range 8.2 – 94.0%), with 
no difference between MSM and heterosexual men. 
Factors associated with vaccine acceptability were 
positive HPV vaccine attitudes, healthcare profes-
sional (HCP) recommendations, perceived risk, HPV 
awareness and knowledge.71 For parents of adolescent 
boys, the perceived benefit of HPV vaccination in 
preventing cancer in males was found to be the most 
important predictor of vaccine acceptability.72 
Political will is essential for HPV vaccination 
programme implementation. New public health in-
terventions, such as the HPV vaccine, demand more 
cost-effectiveness and sustainability evidence in order 
to convince policymakers.73 For successful universal 
vaccination, it will be crucial to educate policy mak-
ers on the merit of including boys in HPV vaccination 
programmes. PATH/LSHTM’s review74 indicated that 
political support was fundamental to successful dem-
onstration and introduction of pilot projects in LMICs. 
There have been a number of studies testing the 
effectiveness of interventions to boost uptake. The 
majority have involved written information to edu-
cated populations, which limits their generalizability, 
while low uptake groups were not targeted,75 although 
there is mounting evidence that using communication 
technologies may increase vaccine rates.76 
CONCLUSION
In high-income countries, unlike cervical can-
cer, there is no reliable and cost-effective screening 
method to prevent cancers attributed to HPV in men. 
In many LMICs, screening methods are not avail-
able for any cancer for either gender.77 In addition, 
in LMICs, higher incidence of certain male cancers, 
lack of effective treatment, high prevalence of HIV, 
and attitudes towards sexual orientation, all support 
a universal vaccination strategy. 
Universal vaccination of all young, adolescent 
women, and with available resources at least for high-
risk groups of men, should be a global health priority. 
Development of multi-purpose STI vaccines for, for 
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example, Hepatitis A and B and HPV should also be 
considered. Political leaders, healthcare providers and 
public health officials in LMICs need to take challeng-
ing and sometimes politically contentious decisions to 
“prevent the preventable”. The pharmaceutical industry 
also should play their part, providing affordable ways 
in which a universal HPV vaccination strategy can 
be realised, particularly in LMICs. Failure to do so 
will result in the continuation of avoidable cervical 
cancer deaths especially in LMICs (whereby 260,000 
women die each year),77 and thousands of men dying 
from other HPV-related cancers.53
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